Osteoarthritis Management with Celecoxib

Introduction to Celecoxib Use

The British Medical Journal recommends using the lowest effective dose of celecoxib for the shortest duration necessary to minimize cardiovascular, gastrointestinal, and renal risks 1
The American College of Rheumatology and the European League Against Rheumatism (EULAR) suggest a treatment sequence starting with core non-pharmacological treatments, followed by paracetamol, then topical NSAIDs, and finally oral NSAIDs or COX-2 inhibitors like celecoxib 1, 2

The guideline recommends that celecoxib should be taken without regard to meal timing, although the specific dosing schedule (200 mg once daily or 100 mg twice daily) may vary based on patient preference and clinical judgment 1

The EULAR guidelines state that celecoxib is not a first-line treatment for osteoarthritis, and should only be considered when paracetamol and topical options provide insufficient relief 1, 2
The treatment sequence should start with core non-pharmacological treatments, including exercise, weight loss if overweight, and patient education, as recommended by the British Medical Journal 1

The British Medical Journal recommends co-prescribing a proton pump inhibitor with celecoxib in patients with advanced age, history of gastrointestinal bleeding, concurrent use of low-dose aspirin, or other gastrointestinal risk factors 1
The EULAR guidelines contraindicate celecoxib in patients with significant cardiovascular risk factors, and recommend against its use in patients with increased cardiovascular risk 2, 3
The British Medical Journal advises using NSAIDs, including celecoxib, with extreme caution or avoiding them in patients with chronic kidney disease, and recommends regular monitoring of renal function during treatment 1

The British Medical Journal and the EULAR guidelines recommend not starting celecoxib before trying paracetamol and topical NSAIDs, unless there are specific contraindications to these first-line agents 1, 2
The guidelines also advise against combining celecoxib with other NSAIDs, as this increases adverse event risk without additional benefit, and against prescribing without gastroprotection in high-risk patients 1, 2
Furthermore, the EULAR guidelines recommend not using celecoxib in patients with significant cardiovascular disease, given the contraindication for COX-2 inhibitors in this population 2, 3
Regular reassessment of treatment is recommended, rather than continuing indefinitely without evaluation of ongoing benefit versus risk 1, 2